GlassScriptPhysician profile
Sajjad Ahmad
NPI 1013359173
$7,881.88
in general payments reported to CMS, 2019-2025
29 companies · $2,440 in 2025
The $2,440 reported for 2025 was more than what 86% of Cardiovascular Disease providers received nationally (typical 2025 total: $433).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $2,333 · 2020: $1,318 · 2021: $185 · 2022: $730 · 2023: $225 · 2024: $650 · 2025: $2,440.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Travel and Lodging: $2,122 · Food and Beverage: $1,193.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Travel and Lodging | $2,122.12 |
| Food and Beverage | $1,193.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Medtronic Vascular, INC. | $1,984.68 | 2019 | |
| Heartflow, INC. | $1,211.25 | 2020-2024 | |
| Siemens Medical Solutions USA, INC. | $1,166.81 | 2025 | Biograph Vision 600 (8 Ring/64 Ct) |
| Ge Healthcare | $1,056.91 | 2025 | |
| E.R. Squibb & Sons, L.L.C. | $370.09 | 2019-2025 | Camzyos, Eliquis |
| Boston Scientific Corporation | $306.30 | 2022-2024 | Watchman Access System, Watchman Flx, Lux-Dx Insertable Cardiac Monitor |
| Amgen INC. | $276.81 | 2019-2025 | Repatha, Repatha |
| Pfizer INC. | $212.54 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $201.84 | 2019-2022 | |
| Edwards Lifesciences Corporation | $173.32 | 2021-2024 | Sapien 3 Ultra Resilia |
| Biotronik INC. | $162.38 | 2020-2022 | |
| Astrazeneca Pharmaceuticals LP | $159.29 | 2019-2025 | |
| Sanofi-Aventis U.S. LLC | $108.49 | 2019-2022 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $70.07 | 2019-2025 | Lifevest |
| Novartis Pharmaceuticals Corporation | $58.36 | 2019-2023 |
Show all 29 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Becton, Dickinson and Company | $43.29 | 2025 | Hemosphere |
| Alnylam Pharmaceuticals INC. | $40.49 | 2019-2024 | Amvuttra |
| Lantheus Medical Imaging, INC. | $35.82 | 2022 | |
| Esperion Therapeutics, INC. | $32.18 | 2021-2025 | Nexletol |
| Boehringer Ingelheim Pharmaceuticals, INC. | $31.41 | 2020 | |
| Medtronic, INC. | $28.64 | 2022 | |
| Regeneron Healthcare Solutions, INC. | $26.28 | 2019 | |
| Amarin Pharma, INC. | $25.56 | 2019-2021 | |
| Penumbra, INC. | $24.95 | 2025 | Indigo System |
| Biosense Webster, INC. | $18.38 | 2022 | |
| Merck Sharp & Dohme LLC | $16.84 | 2023 | Verquvo |
| Braemar Manufacturing, LLC | $13.97 | 2019 | |
| Chiesi USA, INC. | $12.87 | 2021 | |
| Gilead Sciences, INC. | $12.06 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Sajjad Ahmad listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.